SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-031423
Filing Date
2022-11-10
Accepted
2022-11-10 17:01:00
Documents
69
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1297668
2 ex10-2.htm EX-10.2 13203
3 ex10-3.htm EX-10.3 12069
4 ex31-1.htm EX-31.1 11634
5 ex31-2.htm EX-31.2 18191
6 ex32-1.htm EX-32.1 4896
7 ex32-2.htm EX-32.2 4853
  Complete submission text file 0001493152-22-031423.txt   7114323

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE mymd-20220930.xsd EX-101.SCH 51031
9 XBRL CALCULATION FILE mymd-20220930_cal.xml EX-101.CAL 52589
10 XBRL DEFINITION FILE mymd-20220930_def.xml EX-101.DEF 263340
11 XBRL LABEL FILE mymd-20220930_lab.xml EX-101.LAB 466608
12 XBRL PRESENTATION FILE mymd-20220930_pre.xml EX-101.PRE 371807
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1162977
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 221378296
SIC: 2835 In Vitro & In Vivo Diagnostic Substances